Hence, to harness the BRCAness-like phenotype of our in vitro CRC model, and with the aim to valorise our newly identified MortaparibPlus as a multimodal anticolorectal-cancer candidate molecule, we next investigated its effect on PARP1 signalling. This evidence concerns the gene PARP1 and colorectal carcinoma.